Lung cancer study reveals hidden impact of weight loss on treatment
NCT ID NCT07559526
First seen May 08, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tracked 25 adults with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured their weight, muscle mass, and diet to understand how nutrition and muscle loss (sarcopenia) relate to treatment side effects and quality of life. The goal was to gather information, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Complex of Vigo
Vigo, Pontevedra, 36312, Spain
Conditions
Explore the condition pages connected to this study.